We found that several MEK inhibitors, including refametinib and trametinib, decrease MYC expression in CML cells whereas the PI3‐kinase/mTOR blocker BEZ235 showed no effects. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.